The human cytochrome P450 (CYP) allele nomenclature website: A peer-reviewed database of CYP variants and their associated effects

Human Genomics

Volumn 4, Issue 4, 2010, Pages 278-281

  Sim, Sarah C ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adverse drug reactions; Cytochrome P450 oxidoreductase (POR); Drug metabolism; Drug response; Haplotypes; Pharmacogenetics

Indexed keywords

CYTOCHROME P450; XENOBIOTIC AGENT;

ALLELE; ARTICLE; CLASSIFICATION; GENETIC DATABASE; GENETIC VARIABILITY; GENETICS; HUMAN; INTERNET; METABOLISM; NOMENCLATURE; PEER REVIEW;

ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, GENETIC; GENETIC VARIATION; HUMANS; INTERNET; PEER REVIEW; TERMINOLOGY AS TOPIC; XENOBIOTICS;

EID: 85027954420     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/1479-7364-4-4-278     Document Type: Article

References (14)

1. Eichelbaum, M., Ingelman-Sundberg, M. and Evans, W.E. (2006), ‘Pharmacogenomics and individualized drug therapy’, Annu. Rev. Med. Vol. 57, pp. 119–137.
2. Bertz, R.J. and Granneman, G.R. (1997), ‘Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic inter-actions’, Clin. Pharmacokinet. Vol. 32, pp. 210–258.
3. Evans, W.E. and Relling, M.V. (1999), ‘Pharmacogenomics: Translating functional genomics into rational therapeutics’, Science Vol. 286, pp. 487–491.
4. Weinshilboum, R. (2003), ‘Inheritance and drug response’, N. Engl. J. Med. Vol. 348, pp. 529–537.
5. Ingelman-Sundberg, M. (2004), ‘Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future’, Trends Pharmacol. Sci. Vol. 25, pp. 193–200.
6. Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.L. et al. (2004), ‘Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response’, Mol. Psychiatry Vol. 9, pp. 442–473.
7. Pirmohamed, M. and Park, B.K. (2001), ‘Genetic susceptibility to adverse drug reactions’, Trends Pharmacol. Sci. Vol. 22, pp. 298–305.
8. Ingelman-Sundberg, M., Oscarson, M. and McLellan, R.A. (1999), ‘Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment’, Trends Pharmacol. Sci. Vol. 20, pp. 342–349.
9. Shows, T.B., McAlpine, P.J., Boucheix, C., Collins, F.S. et al. (1987), ‘Guidelines for human gene nomenclature. An international system for human gene nomenclature (ISGN, 1987)’, Cytogenet. Cell Genet. Vol. 46, pp. 11–28.
10. Daly, A.K., Brockmoller, J., Broly, F., Eichelbaum, M. et al. (1996), ‘Nomenclature for human CYP2D6 alleles’, Pharmacogenetics Vol. 6, pp. 193–201.
11. Antonarakis, S.E. (1998), ‘Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group’, Hum. Mutat. Vol. 11, pp. 1–3.
12. den Dunnen, J.T. and Antonarakis, S.E. (2001), ‘Nomenclature for the description of human sequence variations’, Hum. Genet. Vol. 109, pp. 121–124.
13. Nelson, D.R., Zeldin, D.C., Hoffman, S.M., Maltais, L.J. et al. (2004), ‘Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseu-dogenes and alternative-splice variants’, Pharmacogenetics Vol. 14, pp. 1–18.
14. Sim, S.C., Miller, W.L., Zhong, X.B., Arlt, W. et al. (2009), ‘Nomenclature for alleles of the cytochrome P450 oxidoreductase gene’, Pharmacogenet. Genomics Vol. 19, pp. 565–566.